A grid, not a headline
The tirzepatide block is a genuine two-axis table: a starter dose band and a maintenance dose band, each priced at one month, three months and six months. Semaglutide gets the simpler treatment — one price for every dose, on the same three terms. Nothing is a from figure and nothing is an as-low-as figure.
That is rare enough to be the main reason to read this seller's page. Most of this market publishes one number and leaves the reader to discover, at intake, that it was a floor, a promotional rate, or a twelve-month prepayment.
Three lanes that do not buy medicine
The brand-name lane is a management service: a prescription fee once, then a monthly charge, with the prescription sent to the patient's own pharmacy to be paid for there. The newest oral brand-name product is priced the same way, dispensed by the manufacturer's own pharmacy. And there is a monthly bridge described as running alongside Part D insurance.
None of those figures buys a drug, and all three are considerably smaller than the compounded figures next to them. We have recorded each as excluding the medication so that no total on this site can add one of them up as though it were a month's supply.
The insurance work is itemised separately again — an eligibility check, a prior-authorisation submission with one appeal, an activation step and an ongoing monthly support charge. That is a level of detail nothing else in this comparison publishes.
What it does not tell you
No compounding pharmacy is named. No individual prescribing clinician is named — the about page describes a clinical team and gives first names with credentials. No service area is published.
The oral GLP-1 lane is priced without the molecule being named on the pricing page, so what is in the tablet is not established there. And the domain named in its FDA warning letter is not the domain a reader ends up on: the lettered address redirects to a second one, and the second one is where the catalogue lives.
Body Good's published pricing
| Medication | Price | Verified |
|---|---|---|
| Tirzepatide (compounded) | $299/mothe one-month rate for the starter dose tier; the same row prints $279/mo on a three-month term and $259/mo on a six-month term | September 2026source |
| Tirzepatide (compounded) | $349/mothe one-month rate for the maintenance dose tier; $329/mo on three months and $319/mo on six | September 2026source |
| Semaglutide (compounded) | $169/mothe one-month rate, flat across every published dose; $149/mo on three months and $139/mo on six | September 2026source |
| Glp-1 (compounded-oral) | $129/mopublished as "Oral GLP-1 / mo $129" and "From $129/mo"; the pricing page does not name the molecule in this lane | September 2026source |
| Glp-1 (brand) | $45/moa management fee of $45/mo after a $55 prescription fee; ⛔ the drug is NOT in this figure — the prescription is sent to the patient's own pharmacy and paid for there | September 2026source |
| Orforglipron (brand) | $45/moa management fee of $45/mo after a $49 prescription fee; ⛔ the drug is NOT in this figure — it is dispensed by the manufacturer pharmacy and paid for there | September 2026source |
| Glp-1 (brand) | $39/mopublished as "Medicare GLP-1 Bridge · Part D insurance · $39/mo"; ⛔ this is a navigation service alongside a Part D plan, not a drug price | September 2026source |
compareglp may earn a commission when a reader signs up with a provider through a link on this site. 4 of the 198 providers reviewed here are paid partners today; the other 194 are not. See how this works.
See Body Good's current price →Good fit if
- Readers who want dose tier and plan term priced against each other rather than blended into one figure.
- Buyers weighing a compounded route against a brand-name prescription they will fill themselves.
- People on Medicare who want to see what an insurance-adjacent service costs.
- Anyone who wants prior authorisation work priced as a line item.
Look elsewhere if
- Readers who might mistake the brand-name or Part D figures for the price of medication; they are service fees.
- Buyers who need a named compounding pharmacy or a named prescribing clinician.
- Anyone who needs the oral lane's molecule identified before ordering.
- Readers who need a service-area list, or for whom an FDA warning letter is disqualifying.
How this review was verified
- Re-read the pricing page, the about page and the HIPAA notice on 7 September 2026, comparing requested to effective URLs and running a nonsense path against the host in the same run, which returned a 404.
- Recorded every cell of the tirzepatide grid rather than its lowest value, and stored the one-month figures as the price with the term rates in the qualifier.
- Marked the brand-name, oral-brand and Part D rows as excluding the medication, as declared fields rather than as something inferred from their wording.
- Read the two company names off the HIPAA notice in full sentences, and rejected a duplicated navigation label that a pattern match returns as a company.
- Screened the brand against FDA's live warning-letter datatable with a positive and a negative control in the same invocation, and re-fetched the letter to confirm its title matches the reference number and date; a minted nonsense letter path returned a 404 in the same run.